Mouse models of autoimmune uveitis

Current Pharmaceutical Design

Volumn 21, Issue 18, 2015, Pages 2453-2467

  Klaska, Izabela P ^a   Forrester, John V ^a,b,c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c LIONS EYE INSTITUTE   (Australia)

Author keywords

Animal models; Autoimmunity; Inflammation; Th1; Th17; Uveitis; Uveitogenic antigens

Indexed keywords

PEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOPTIVE TRANSFER; ANIMAL MODEL; ARTICLE; AUTOIMMUNE UVEITIS; AUTOIMMUNITY; CLINICAL ASSESSMENT; DENDRITIC CELL; ENDOTOXIN-INDUCED UVEITIS; EXPERIMENTAL AUTOIMMUNE ANTERIOR UVEITIS; EXPERIMENTAL AUTOIMMUNE DISEASE; EXPERIMENTAL OCULAR INFLAMMATION; EXPERIMENTAL UVEITIS; EXPERIMENTAL UVEORETINITIS; GENETIC SIMILARITY; HUMAN; IMMUNOPATHOGENESIS; IRIDOCYCLITIS; MOLECULAR PATHOLOGY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; UVEORETINITIS; ANIMAL; AUTOIMMUNE DISEASES; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY; UVEITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MICE; UVEITIS;

EID: 84929648611     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150316122928     Document Type: Article

References (134)

1. [1] Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990; 14(5-6): 303-8.
2. [2] The World Health Report, WHO Global data on visual impairments. 2010; http://www.who.int/blindness/GLOBALDATAFINALforweb.pdf.
3. [3] Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80(9): 844-8.
4. [4] Lee RW, Nicholson LB, Sen HN, et al. Autoimmune and autoinflammatory mechanisms in uveitis. Semin Immunopathol 2014; 36(5): 581-94.
5. [5] Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140(3): 509-16.
6. [6] Forrester JV, Klaska IP, Yu T, Kuffova L. Uveitis in mouse and man. Int Rev Immunol 2013; 32(1): 76-96.
7. [7] Rosenbaum JT, Rosenzweig HL, Smith JR, Martin TM, Planck SR. Uveitis secondary to bacterial products. Ophthal Res 2008; 40(3-4): 165-8.
8. [8] Kongyai N, Sirirungsi W, Pathanapitoon K, et al. Viral causes of unexplained anterior uveitis in Thailand. Eye (Lond) 2012; 26(4): 529-34.
9. [9] de Groot-Mijnes JD, de Visser L, Zuurveen S, et al. Identification of new pathogens in the intraocular fluid of patients with uveitis. Am J Ophthalmol 2010; 150(5): 628-36.
10. [10] Wildner G, Diedrichs-Mohring M. Autoimmune uveitis induced by molecular mimicry of peptides from rotavirus, bovine casein and retinal S-antigen. Eur J Immunol 2003; 33(9): 2577-87.
11. [11] Rosenbaum JT, Tammaro J, Robertson JE, Jr. Uveitis precipitated by nonpenetrating ocular trauma. Am J Ophthalmol 1991; 112(4): 392-5.
12. [12] Dick A, Forrester JV, Okada AA. Practical Manual of Intraocular Inflammation. USA: Informa Healthcare 2008.
13. [13] Levinson RD, Park MS, Rikkers SM, et al. Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci 2003; 44(2): 653-7.
14. [14] Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Survey Ophthalmol 2005; 50(4): 364-88.
15. [15] Derhaag PJ, van der Horst AR, de Waal LP, Feltkamp TE. HLAB27+ acute anterior uveitis and other antigens of the major histocompatibility complex. Invest Ophthalmol Vis Sci 1989; 30(10): 2160-4.
16. [16] Martin TM, Rosenbaum JT. An update on the genetics of HLA B27-associated acute anterior uveitis. Ocul Immunol Inflamm 2011; 19(2): 108-14.
17. [17] Brewerton DA, Nicholls A, Caffrey M, Walters D, James DCO. Acute anterior uveitis and HL-A 27. Lancet 1973; 302(7836): 994-6.
18. [18] Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol 2000; 84(3): 259-63.
19. [19] Atan D, Fraser-Bell S, Plskova J, et al. Punctate inner choroidopathy and multifocal choroiditis with panuveitis share haplotypic associations with IL10 and TNF loci. Invest Ophthalmol Vis Sci 2011; 52(6): 3573-81.
20. [20] Atan D, Fraser-Bell S, Plskova J, et al. Cytokine polymorphism in noninfectious uveitis. Investig Ophthalmol Visual Sci 2010; 51(8): 4133-42.
21. [21] Atan D, Turner SJ, Kilmartin DJ, et al. Cytokine gene polymorphism in sympathetic ophthalmia. Investig Ophthalmol Vis Sci 2005; 46(11): 4245-50.
22. [22] Gregoire MA, Kodjikian L, Varron L, Grange JD, Broussolle C, Seve P. Characteristics of uveitis presenting for the first time in the elderly: analysis of 91 patients in a tertiary center. Ocular Immunol Inflamm 2011; 19(4): 219-26.
23. [23] Yoser SL, Forster DJ, Rao NA. Pathology of intermediate uveitis. Develop Ophthalmol 1992; 23: 60-70.
24. [24] Ben Ezra D, Forrester JV. Fundal white dots: the spectrum of a similar pathological process. Br J Ophthalmol 1995; 79(9): 856-60.
25. [25] Kiew S, Forrester JV, Chee SP, Kuffova L. Intravenous 'pulse' methylprednisolone for the treatment of inflammatory cystoid macular oedema. Br J Ophthalmol 2012; 96(12): 1531-3.
26. [26] de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human Santigen determinant recognition in uveitis. Investig Ophthalmol Vis Sci 2001; 42(13): 3233-8.
27. [27] de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behcet's disease patients and controls. Investig Ophthalmol Vis Sci 2000; 41(11): 3480-4.
28. [28] de Smet MD, Yamamoto JH, Mochizuki M, et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol 1990; 110(2): 135-42.
29. [29] Forrester JV, Stott DI, Hercus KM. Naturally occurring antibodies to bovine and human retinal S antigen: a comparison between uveitis patients and healthy volunteers. Br J Ophthalmol 1989; 73(2): 155-9.
30. [30] Amadi-Obi A, Yu CR, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13(6): 711-8.
31. [31] Chu CJ, Herrmann P, Carvalho LS, et al. Assessment and in vivo scoring of murine experimental autoimmune uveoretinitis using optical coherence tomography. PloS One 2013; 8(5): e63002.
32. [32] Chen J, Qian H, Horai R, Chan CC, Caspi RR. Use of optical coherence tomography and electroretinography to evaluate retinal pathology in a mouse model of autoimmune uveitis. PloS One 2013; 8(5): e63904.
33. [33] Copland DA, Wertheim MS, Armitage WJ, Nicholson LB, Raveney BJ, Dick AD. The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation. Invest Ophthalmol Vis Sci 2008; 49(12): 5458-65.
34. [34] de Smet MD, Yamamoto JH, Mochizuki M, et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol 1990; 110(2): 135-42.
35. [35] Nussenblatt RB, Gery I, Ballintine EJ, Wacker WB. Cellular immune responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol 1980; 89(2): 173-9.
36. [36] Caspi RR, Silver PB, Luger D, et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Res 2008; 40(3-4): 169-74.
37. [37] Gery I, Wiggert B, Redmond TM, et al. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest Ophthalmol Vis Sci 1986; 27(8): 1296-300.
38. [38] Caspi RR, Roberge FG, Chan CC, et al. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol 1988; 140(5): 1490-5.
39. [39] Adamus G, Chan CC. Experimental autoimmune uveitides: multiple antigens, diverse diseases. Int Rev Immunol 2002; 21(2-3): 209-29.
40. [40] Caspi RR, Silver PB, Luger D, et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Res 2008; 40(3-4): 169-74.
41. [41] Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McMenamin PG. Experimental autoimmune uveoretinitis: a model system for immunointervention: a review. Curr Eye Res 1992; 11 (Suppl): 33-40.
42. [42] Dua HS, Abrams M, Barrett JA, Gregerson DS, Forrester JV, Donoso LA. Epitopes and idiotypes in experimental autoimmune uveitis: a review. Curr Eye Res 1992; 11 (Suppl): 59-65.
43. [43] Yamaki K, Ohono S. Animal models of Vogt-Koyanagi-Harada disease (sympathetic ophthalmia). Ophthalmic Res 2008; 40(3-4): 129-35.
44. [44] Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol 1992; 148(8): 2384-9.
45. [45] Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci 2000; 41(1): 127-31.
46. [46] Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002; 161(5): 1669-77.
47. [47] Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci 1999; 40(13): 3177-85.
48. [48] Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukocyte Biol 2001; 70(6): 849-60.
49. [49] Silver PB, Chan CC, Wiggert B, Caspi RR. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999; 40(12): 2898-905.
50. [50] Caspi RR. Experimental Autoimmune Uveoretinitis in the Rat and Mouse. Current Protocols in Immunology: John Wiley & Sons, Inc. 2001.
51. [51] Linthicum DS, Munoz JJ, Blaskett A. Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 1982; 73(2): 299-310.
52. [52] Sudweeks JD, Todd JA, Blankenhorn EP, et al. Locus controlling Bordetella pertussis-induced histamine sensitization (Bphs), an autoimmune disease-susceptibility gene, maps distal to T-cell receptor beta-chain gene on mouse chromosome 6. Proc Natl Acad Sci USA 1993; 90(8): 3700-4.
53. [53] Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2(2): 102-7.
54. [54] Racke MK, Hu W, Lovett-Racke AE. PTX cruiser: driving autoimmunity via TLR4. Trends Immunol 2005; 26(6): 289-91.
55. [55] Shao H, Liao T, Ke Y, Shi H, Kaplan HJ, Sun D. Severe chronic experimental autoimmune uveitis (EAU) of the C57BL/6 mouse induced by adoptive transfer of IRBP1-20-specific T cells. Exp Eye Res 2006; 82(2): 323-31.
56. [56] Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16(4): 406-12.
57. [57] Tang J, Zhu W, Silver PB, Su SB, Chan CC, Caspi RR. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol 2007; 178(9): 5578-87.
58. [58] Taneja V, David CS. HLA class II transgenic mice as models of human diseases. Immunol Rev 1999; 169: 67-79.
59. [59] Pennesi G, Mattapallil MJ, Sun SH, et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Investig 2003; 111(8): 1171-80.
60. [60] Szpak Y, Vieville JC, Tabary T, et al. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci USA 2001; 98(5): 2572-6.
61. [61] de Kozak Y, Camelo S, Pla M. Pathological aspects of spontaneous uveitis and retinopathy in HLA-A29 transgenic mice and in animal models of retinal autoimmunity: relevance to human pathologies. Ophthalmic Res 2008; 40(3-4): 175-80.
62. [62] Taniguchi RT, DeVoss JJ, Moon JJ, et al. Detection of an autoreactive T-cell population within the polyclonal repertoire that undergoes distinct autoimmune regulator (Aire)-mediated selection. Proc Natl Acad Sci USA 2012; 109(20): 7847-52.
63. [63] Kisand K, Peterson P, Laan M. Lymphopenia-induced proliferation in aire-deficient mice helps to explain their autoimmunity and differences from human patients. Front Immunol 2014; 5: 51.
64. [64] Heino M, Peterson P, Kudoh J, et al. APECED mutations in the autoimmune regulator (AIRE) gene. Hum Mutat 2001; 18(3): 205-11.
65. [65] Hubert FX, Kinkel SA, Crewther PE, et al. Aire-deficient C57BL/6 mice mimicking the common human 13-base pair deletion mutation present with only a mild autoimmune phenotype. J Immunol 2009; 182(6): 3902-18.
66. [66] Kuroda N, Mitani T, Takeda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of Aire-deficient mice. J Immunol 2005; 174(4): 1862-70.
67. [67] Jiang W, Anderson MS, Bronson R, Mathis D, Benoist C. Modifier loci condition autoimmunity provoked by Aire deficiency. J Exp Med 2005; 202(6): 805-15.
68. [68] Pontynen N, Miettinen A, Arstila TP, et al. Aire deficient mice do not develop the same profile of tissue-specific autoantibodies as APECED patients. J Autoimmun 2006; 27(2): 96-104.
69. [69] DeVoss J, Hou Y, Johannes K, et al. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 2006; 203(12): 2727-35.
70. [70] Gregerson DS, Torseth JW, McPherson SW, Roberts JP, Shinohara T, Zack DJ. Retinal expression of a neo-self antigen, betagalactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. J Immunol 1999; 163(2): 1073-80.
71. [71] Gregerson DS, Dou C. Spontaneous induction of immunoregulation by an endogenous retinal antigen. Invest Ophthalmol Vis Sci 2002; 43(9): 2984-91.
72. [72] Lai JC, Lobanoff MC, Fukushima A, et al. Uveitis induced by lymphocytes sensitized against a transgenically expressed lens protein. Invest Ophthalmol Vis Sci 1999; 40(11): 2735-9.
73. [73] Lambe T, Leung JC, Ferry H, et al. Limited peripheral T cell anergy predisposes to retinal autoimmunity. J Immunol 2007; 178(7): 4276-83.
74. [74] Horai R, Silver PB, Chen J, et al. Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen. J Autoimmun 2013; 44(0): 21-33.
75. [75] Forrester JV, Worgul BV, Merriam GR, Jr. Endotoxin-induced uveitis in the rat. Graefe's Arch Clin Exp Ophthalmol 1980; 213(4): 221-33.
76. [76] Li Q, Peng B, Whitcup SM, Jang SU, Chan CC. Endotoxin induced uveitis in the mouse: susceptibility and genetic control. Exp Eye Res 1995; 61(5): 629-32.
77. [77] Kozhich AT, Chan CC, Gery I, Whitcup SM. Recurrent intraocular inflammation in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 2000; 41(7): 1823-6.
78. [78] Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Biol 1998; 76(6): 497-512.
79. [79] Bora NS, Kim MC, Kabeer NH, et al. Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body. Invest Ophthalmol Vis Sci 1995; 36(6): 1056-66.
80. [80] Jha P, Manickam B, Matta B, Bora PS, Bora NS. Proteolytic cleavage of type I collagen generates an autoantigen in autoimmune uveitis. J Biol Chem 2009; 284(45): 31401-11.
81. [81] Chen S, Aronow ME, Wang C, Shen D, Chan CC. Classical pathology of sympathetic ophthalmia presented in a unique case. Open Ophthalmol J 2014; 8: 32-8.
82. [82] Forrester JV, Borthwick GM. Clinical relevance of S-antigen induced experimental uveoretinitis. Trans Ophthalmol Soc UK 1983; 103 (Pt 5): 497-502.
83. [83] Forrester JV, Liversidge J, Dua HS, Towler H, McMenamin PG. Comparison of clinical and experimental uveitis. Curr Eye Res 1990; 9 (Suppl): 75-84.
84. [84] Rao NA, Zhang J, Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc 1998; 96: 111-23; discussion 24-6.
85. [85] Palestine AG, Nussenblatt RB, Chan CC, Hooks JJ, Friedman L, Kuwabara T. Histopathology of the subretinal fibrosis and uveitis syndrome. Ophthalmology 1985; 92(6): 838-44.
86. [86] Martin DF, Chan CC, de Smet MD, et al. The role of chorioretinal biopsy in the management of posterior uveitis. Ophthalmology 1993; 100(5): 705-14.
87. [87] Teoh SC, Dick AD. Diagnostic techniques for inflammatory eye disease: past, present and future: a review. BMC Ophthalmol 2013; 13(1): 41.
88. [88] Luger D, Caspi RR. New perspectives on effector mechanisms in uveitis. Semin Immunopathol 2008; 30(2): 135-43.
89. [89] Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205(4): 799-810.
90. [90] Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol 1998; 161(1): 122-7.
91. [91] Tarrant TK, Silver PB, Wahlsten JL, et al. Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med 1999; 189(2): 219-30.
92. [92] Caspi RR, Chan CC, Grubbs BG, et al. Endogenous systemic IFNgamma has a protective role against ocular autoimmunity in mice. J Immunol 1994; 152(2): 890-9.
93. [93] Jones LS, Rizzo LV, Agarwal RK, et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997; 158(12): 5997-6005.
94. [94] Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Investig 2002; 110(4): 493-7.
95. [95] Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421(6924): 744-8.
96. [96] Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13(5): 715-25.
97. [97] Chi W, Yang P, Li B, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007; 119(5): 1218-24.
98. [98] Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49(7): 3058-64.
99. [99] Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013; 120(4): 777-87.
100. [100] Sonoda KH, Sasa Y, Qiao H, et al. Immunoregulatory role of ocular macrophages: the macrophages produce RANTES to suppress experimental autoimmune uveitis. J Immunol 2003; 171(5): 2652-9.
101. [101] Wang L, Yu CR, Kim HP, et al. Key role for IL-21 in experimental autoimmune uveitis. Proc Natl Acad Sci USA 2011; 108(23): 9542-7.
102. [102] Saraswathy S, Rao NA. Photoreceptor mitochondrial oxidative stress in experimental autoimmune uveitis. Ophthalmic Res 2008; 40(3-4): 160-4.
103. [103] Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res 2011; 31(10): 733-44.
104. [104] Nian H, Shao H, O'Brien RL, Born WK, Kaplan HJ, Sun D. Activated gammadelta T cells promote the activation of uveitogenic T cells and exacerbate EAU development. Invest Ophthalmol Vis Sci 2011; 52(8): 5920-7.
105. [105] Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2010; 51(1): 383-9.
106. [106] Tu Z, Li Y, Smith D, et al. Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53(2): 959-66.
107. [107] Khatri S, Lass JH, Heinzel FP, et al. Regulation of endotoxininduced keratitis by PECAM-1, MIP-2, and toll-like receptor 4. Invest Ophthalmol Vis Sci 2002; 43(7): 2278-84.
108. [108] Pandey RK, Yu FS, Kumar A. Targeting toll-like receptor signaling as a novel approach to prevent ocular infectious diseases. Indian J Med Res 2013; 138(5): 609-19.
109. [109] Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: Efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010; 58(1): 55-8.
110. [110] Liversidge J, Thomson AW, Sewell HF, Forrester JV. EAU in the guinea pig: inhibition of cell-mediated immunity and Ia antigen expression by cyclosporin A. Clin Exp Immunol 1987; 69(3): 591-600.
111. [111] Nussenblatt RB, Rodrigues MM, Salinas-Carmona MC, Gery I, Cevario S, Wacker W. Modulation of experimental autoimmune uveitis with cyclosporin A. Arch Ophthalmol 1982; 100(7): 1146-9.
112. [112] Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997; 81(12): 1107-12.
113. [113] Yeh S, Nussenblatt RB, Levy-Clarke GA. Emerging biologics in the treatment of uveitis. Exp Rev Clin Immunol 2007; 3(5): 781-96.
114. [114] Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18(6): 481-6.
115. [115] Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89(6-7): 884-93.
116. [116] Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123(7): 903-12.
117. [117] Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89(5): 533-6.
118. [118] Valentincic NV, de Groot-Mijnes JD, Kraut A, Korosec P, Hawlina M, Rothova A. Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis 2011; 17: 2003-10.
119. [119] Marotte H, Miossec P. Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. Biol Targets Ther 2008; 2(4): 663-9.
120. [120] Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opinion Ophthalmol 2007; 18(6): 481-6.
121. [121] Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009; 17(6): 403-14.
122. [122] Srivastava A, Rajappa M, Kaur J. Uveitis: Mechanisms and recent advances in therapy. Clin Chim Acta Int J Clin Chem 2010; 411(17-18): 1165-71.
123. [123] Forrester JV, Dick AD, McMenamin P.G., Roberts F. The Eye, Basic Sciences in Practice. 3rd ed. USA: Saunders Elsevier 2008.
124. [124] Choi B, Hwang Y, Kwon HJ, et al. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008; 52(2): 87-7.
125. [125] Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annl Rev Med 1999; 50: 507-29.
126. [126] Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29(11): 1247-55.
127. [127] Ralph M. Steinman M. Dendritic cells and vaccines. Proc (Bayl Univ Med Cent) 2008; 21(1): 3–8 2008.
128. [128] Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semimature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol 2013; 4: 438.
129. [129] Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annl Rev Immunol 2003; 21: 685-711.
130. [130] Jiang HR, Muckersie E, Robertson M, Forrester JV. Antigenspecific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells. Invest Ophthalmol Vis Sci 2003; 44(4): 1598-607.
131. [131] Siepmann K, Biester S, Plskova J, Muckersie E, Duncan L, Forrester JV. CD4+CD25+ T regulatory cells induced by LPSactivated bone marrow dendritic cells suppress experimental autoimmune uveoretinitis in vivo. Graefe's Arch Clin Exp Ophthalmol 2007; 245(2): 221-9.
132. [132] Lau AW, Biester S, Cornall RJ, Forrester JV. Lipopolysaccharideactivated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cells. J Immunol 2008; 180(6): 3889-99.
133. [133] Usui Y, Takeuchi M, Hattori T, et al. Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice. Arch Ophthalmol 2009; 127(4): 514-9.
134. [134] Suzuki Y, Yamashita R, Shirota M, et al. Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions. Genome Res 2004; 14(9): 1711-8.